JPRN-jRCT2080221174未知Unknown
GSK2132231A Antigen-Specific Cancer Immunotherapeutic as adjuvant therapy in patients with resected melanoma
GlaxoSmithKline K.K.0 个研究点开始时间: 2010年8月2日最近更新:
适应症
试验速览
- 阶段
- Unknown
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- •Refer to 'GSK Clinical Study Register'
排除标准
- •Refer to 'GSK Clinical Study Register'
研究者
相似试验
进行中（未招募）
3 期
Resected Stage III Melanoma With Macroscopic InvolvementACTRN12609000099224GlaxoSmithKline Biologicals1,300
未知
3 期
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Canceron-Small Cell Lung CancerJPRN-jRCT2080220584GlaxoSmithKline K.K.
已完成
2 期
A Study to Test the Benefit of a New Anti-cancer Treatment in Patients With Unresectable Advanced MelanomaMelanomaNCT00942162GlaxoSmithKline125
终止
3 期
A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their TumorMelanomaNCT00796445GlaxoSmithKline1,351
终止
3 期
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung CancerLung Cancer, Non-Small CellNCT00480025GlaxoSmithKline2,278